Researchers at The University of Nottingham have identified three sets of genetic markers that could potentially pave the way for...
Findings could provide a new therapeutic target for glioblastoma, a new study reports.
According to a new study, computer modeling has been able to identify a molecule which inhibits a transient cellular event that drives glioblastoma brain cancer.
Researchers report an experimental treatment has shown to be able to stop treatment resistant glioblastoma in human cells and mouse models.
Researchers have identified a gene network that regulates the development of motor neurons during embryonic development.
Senolytic drugs administered to mice reduced senescent cells around amyloid plaques by more than 90% and decreased neuroinflammation by 50%. Mice treated with the drug combination also showed improvements in spatial memory, compared to other Alzheimer's model mice who received no treatment. The findings could have positive implications for the treatment of Alzheimer's disease in people with the condition.
Using stem cells from candidates with Down syndrome to create an organoid, and employing mouse models, researchers pinpoint a gene linked to memory impairments and cognitive problems in Down syndrome. Inhibiting the OLIG2 gene leads to cognitive and memory improvements in mouse models of Down. Researchers hope their findings lead to an in utero treatment that targets the gene and helps reverse abnormal brain development.
Using computer assisted technology to map cell types and molecular cascades, researchers have discovered potential new treatment strategies for recurrent Sonic Hedgehog Medulloblastoma.
